TY - BOOK ID - 137001417 TI - Oncolytic Virus Immunotherapy AU - Marchini, Antonio AU - Ilkow, Carolina S. AU - Melcher, Alan PY - 2022 PB - Basel MDPI - Multidisciplinary Digital Publishing Institute DB - UniCat KW - oncolytic viruses KW - melanoma KW - immunotherapy KW - checkpoint inhibitors KW - combinatory therapy KW - reovirus KW - oncolytic virus KW - adenovirus KW - oncolytic KW - virotherapy KW - targeting KW - immunogenic cell death KW - αvβ6 integrin KW - oncolytic adenovirus KW - cancer immunotherapy KW - multi-stage KW - immunostimulatory KW - arming KW - HSV-1 KW - clinical trials KW - newcastle disease virus KW - NDV KW - cancer KW - immune checkpoint inhibitor KW - PD-1 KW - PD-L1 KW - CTLA-4 KW - type I interferon KW - herpes simplex virus KW - retargeted virus KW - tropism retargeting KW - tumor KW - checkpoint inhibitor KW - vaccination KW - antigen-agnostic vaccination KW - HER2 KW - parvovirus KW - tumor microenvironment KW - combination therapy KW - glioblastoma KW - pancreatic cancer KW - colorectal cancer KW - measles virus KW - vector engineering KW - immune checkpoint blockade KW - antitumor immune response KW - delivery KW - genetic modification KW - biomarkers KW - personalized oncolyticvirotherapy KW - class I HLA KW - immunosurveillance KW - immunoediting KW - oncogenic signaling KW - RAS KW - DNA methyltransferase inhibitor (DNMTi) KW - viral mimicry KW - epigenetic silencing KW - adoptive T cell therapy KW - CAR T cell KW - pancreatic ductal adenocarcinoma KW - vesicular stomatitis virus KW - small molecule KW - cancer immune therapy KW - cancer therapy KW - n/a UR - https://www.unicat.be/uniCat?func=search&query=sysid:137001417 AB - Dear Readers, Oncolytic Viruses (OV) are self-propagating agents that can selectively induce the lysis of cancer cells while sparing normal tissues. OV-mediated cancer cell death is often immunogenic and triggers robust anticancer immune responses and immunoconversion of tumor microenvironments. This makes oncolytic virotherapy a promising new form of immunotherapy and OVs ideal candidates for combination therapy with other anticancer agents, including other immunotherapeutics. There are more than 40 OVs from nine different families in clinical development and many more at the preclinical stage. Each OV has its own unique characteristics, its pros and cons. Although herpes simplex virus is currently the lead clinical agent, a real champion among the OVs has not yet emerged, justifying the continuous development and optimization of these agents. This book, “Oncolytic Virus Immunotherapy”, summarizes the state-of-the-art and gives a comprehensive overview of the OV arena with a particular focus on new trends, directions, challenges, and opportunities. ER -